2020-002295-13: Evaluation of the efficacy, safety and tolerability of alisporivir for the treatment of hospitalised patients with infections due to SARS-CoV-2 (COVID-19). Evaluation l’efficacité, la sécurité et la tolérance de l'alisporivir chez des patients hospitalisés pour une infection par le SARS- CoV-2 (COVID-19). |
|
|
| Not yet recruiting | 2 | 100 | Europe | alisporivir, ALV, DEB025, Oral solution | Assistance Publique - Hôpitaux Paris, DEBIOPHARM SA | The study population will consist of adults (18-80 years old) hospitalised for ≤48 hours prior to randomisation with a diagnosis of COVID-19 based on symptoms onset and SARS-CoV-2 RT-PCR test positive from nasopharyngeal swab. Patients with ARDS or patients requiring mechanical ventilation at screening or randomisation will be excluded, Adults hospitalised with a diagnosis of COVID-19., Diseases [C] - Virus Diseases [C02] | | | | |
2017-002213-60: A study to investigate the safety, tolerability, and efficacy of SGT-001 in male adolescents and children with Duchenne muscular dystrophy |
|
|
| Not yet recruiting | 1/2 | 32 | Europe | SGT-001, rAAV9-CK8-h-μD5, Infusion | Solid Biosciences Inc., Solid Biosciences Inc. | Duchenne muscular dystrophy, Duchenne muscular dystrophy, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
